PL378435A1 - Nowe szczepy Bifidobacterium zdolne do wytwarzania glutaminy - Google Patents
Nowe szczepy Bifidobacterium zdolne do wytwarzania glutaminyInfo
- Publication number
- PL378435A1 PL378435A1 PL378435A PL37843504A PL378435A1 PL 378435 A1 PL378435 A1 PL 378435A1 PL 378435 A PL378435 A PL 378435A PL 37843504 A PL37843504 A PL 37843504A PL 378435 A1 PL378435 A1 PL 378435A1
- Authority
- PL
- Poland
- Prior art keywords
- bifidobacterium
- colitis
- strains
- days
- patients
- Prior art date
Links
- 241000186000 Bifidobacterium Species 0.000 title abstract 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title abstract 3
- 206010009887 colitis Diseases 0.000 abstract 5
- 229920003045 dextran sodium sulfate Polymers 0.000 abstract 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 abstract 2
- 241000700159 Rattus Species 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 206010070545 Bacterial translocation Diseases 0.000 abstract 1
- 208000037112 Intestinal Failure Diseases 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- 241000186606 Lactobacillus gasseri Species 0.000 abstract 1
- 241000186605 Lactobacillus paracasei Species 0.000 abstract 1
- 241000700157 Rattus norvegicus Species 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000007375 bacterial translocation Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000009266 disease activity Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000002443 hepatoprotective effect Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000008383 multiple organ dysfunction Effects 0.000 abstract 1
- 230000008092 positive effect Effects 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000005070 sampling Methods 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000005945 translocation Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0300245A SE526711C2 (sv) | 2003-01-31 | 2003-01-31 | Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav |
| US44727403P | 2003-02-14 | 2003-02-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL378435A1 true PL378435A1 (pl) | 2006-04-03 |
| PL212096B1 PL212096B1 (pl) | 2012-08-31 |
Family
ID=20290264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL378435A PL212096B1 (pl) | 2003-01-31 | 2004-01-27 | Wyizolowane szczepy Bifidobacterium infantis i środek farmaceutyczny |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7947482B2 (pl) |
| EP (1) | EP1587913B1 (pl) |
| JP (1) | JP4540664B2 (pl) |
| CN (1) | CN100558883C (pl) |
| AT (1) | ATE496115T1 (pl) |
| AU (1) | AU2004208084B2 (pl) |
| BR (1) | BRPI0407176B8 (pl) |
| CA (1) | CA2514659C (pl) |
| DE (1) | DE602004031079D1 (pl) |
| DK (1) | DK1587913T3 (pl) |
| ES (1) | ES2362496T3 (pl) |
| PL (1) | PL212096B1 (pl) |
| RU (1) | RU2352628C2 (pl) |
| SE (1) | SE526711C2 (pl) |
| WO (1) | WO2004067731A1 (pl) |
| ZA (1) | ZA200505777B (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006296837B2 (en) | 2005-09-28 | 2012-12-13 | Nordic Rebalance A/S | Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effectors |
| PL1951273T3 (pl) * | 2005-10-06 | 2014-07-31 | Probi Ab | Zastosowanie lactobacillus do leczenia chorób autoimmunologicznych |
| JP5837879B2 (ja) * | 2010-07-05 | 2015-12-24 | 株式会社明治 | 腸内腐敗物質の低減作用を有するビフィズス菌 |
| CL2010001124A1 (es) | 2010-10-14 | 2011-01-21 | Univ De Concepcion 50% Ma Loreto Ormeno 50% | Alimento funcional probiotico que comprende cepas viables de lactobacillus sp.; uso de dicho alimento funcional para contrarestar los efectos colaterales de la quimioterapia. |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| CN103131647B (zh) * | 2011-11-29 | 2017-06-27 | 上海上药信谊药厂有限公司 | 婴儿双歧杆菌及其制剂 |
| BR112014021388A2 (pt) | 2012-02-29 | 2017-07-18 | Ethicon Endo Surgery Inc | composições de microbiota e métodos rela-cionados às mesmas |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| GB2551642B (en) | 2014-10-31 | 2020-09-23 | Pendulum Therapeutics Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| AU2018326705A1 (en) | 2017-08-30 | 2020-03-05 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| CN108330166A (zh) * | 2017-09-06 | 2018-07-27 | 深圳市百澳飞生物技术有限公司 | 一种酶制剂的饲用活性评估方法 |
| RU2699967C1 (ru) * | 2018-12-25 | 2019-09-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Способ комплексного лечения энтеральной недостаточности у детей с тяжелой термической травмой |
| US11045507B2 (en) | 2019-02-21 | 2021-06-29 | Ewelina Sosnowska-Turek | Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59155321A (ja) | 1983-02-25 | 1984-09-04 | Riyoushiyoku Kenkyukai | 整腸用製剤 |
| DE3406772A1 (de) * | 1984-02-24 | 1986-03-13 | Angelo 8137 Berg Schuler | Diaetetisches mittel zur herabsetzung der harnstoffkonzentration in koerperfluessigkeiten und seine herstellung |
| SE9002732D0 (sv) | 1990-08-24 | 1990-08-24 | Kabivitrum Ab | Product containing growth factor |
| IT1254210B (it) | 1992-02-10 | 1995-09-14 | Simone Claudio De | Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego |
| JP3623977B2 (ja) * | 1993-10-29 | 2005-02-23 | 明治乳業株式会社 | 潰瘍性大腸炎治療剤 |
| JP4852681B2 (ja) * | 1996-02-28 | 2012-01-11 | 雪印メグミルク株式会社 | 腸管内細胞溶解活性抑制剤 |
| IT1288119B1 (it) | 1996-06-28 | 1998-09-10 | Renata Maria Anna Ve Cavaliere | Composizioni dietetiche da utilizzare nell'alimentazione per via enterica |
| US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| ID29150A (id) * | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| US6468525B1 (en) | 1999-08-10 | 2002-10-22 | Renew Life, Inc. | Probiotic formulation |
| AU2001262966A1 (en) | 2000-05-03 | 2001-11-12 | University Of Maryland, Baltimore | Oral gram (+) bacteria and glutamine composition for prevention and/or treatmentof gastro-intestinal dysfunctions including inflammation in the gastro-intestin al tract, neonatal necrotizing enterocolitis (nec) and bacterial sepsis |
| AU2001265253A1 (en) * | 2000-07-07 | 2002-01-21 | First Circle Medical, Inc. | Treatment of hiv using hyperthermia |
| JP2002186422A (ja) * | 2000-12-22 | 2002-07-02 | Morinaga Milk Ind Co Ltd | ラクトバシラス・ガッセリ及びビフィドバクテリウム属の菌を含有する非発酵食品 |
| FI109602B (fi) * | 2001-01-25 | 2002-09-13 | Valio Oy | Probioottiyhdistelmä |
| PL367083A1 (pl) | 2001-02-06 | 2005-02-21 | Societe Des Produits Nestle S.A. | Wiązanie endotoksyn przez bakterie kwasu mlekowego i bifidobakterie |
| US20030017192A1 (en) * | 2001-06-19 | 2003-01-23 | Hanny Kanafani | Process for producing extended shelf-life ready-to-use milk compositions containing probiotics |
| PE20030284A1 (es) * | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de bifidobacterium |
| JP3364491B2 (ja) * | 2002-07-25 | 2003-01-08 | 株式会社アトリエ・ド・フロマージュ | ヨーグルトおよびその製造方法 |
-
2003
- 2003-01-31 SE SE0300245A patent/SE526711C2/sv not_active IP Right Cessation
-
2004
- 2004-01-27 CN CNB2004800088252A patent/CN100558883C/zh not_active Expired - Lifetime
- 2004-01-27 DE DE602004031079T patent/DE602004031079D1/de not_active Expired - Lifetime
- 2004-01-27 RU RU2005127331/13A patent/RU2352628C2/ru active
- 2004-01-27 EP EP04705562A patent/EP1587913B1/en not_active Expired - Lifetime
- 2004-01-27 JP JP2006502776A patent/JP4540664B2/ja not_active Expired - Lifetime
- 2004-01-27 ZA ZA200505777A patent/ZA200505777B/en unknown
- 2004-01-27 PL PL378435A patent/PL212096B1/pl unknown
- 2004-01-27 ES ES04705562T patent/ES2362496T3/es not_active Expired - Lifetime
- 2004-01-27 WO PCT/SE2004/000098 patent/WO2004067731A1/en active Application Filing
- 2004-01-27 US US10/543,604 patent/US7947482B2/en active Active
- 2004-01-27 DK DK04705562.9T patent/DK1587913T3/da active
- 2004-01-27 CA CA2514659A patent/CA2514659C/en not_active Expired - Lifetime
- 2004-01-27 BR BRPI0407176A patent/BRPI0407176B8/pt not_active IP Right Cessation
- 2004-01-27 AT AT04705562T patent/ATE496115T1/de not_active IP Right Cessation
- 2004-01-27 AU AU2004208084A patent/AU2004208084B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200505777B (en) | 2007-12-27 |
| BRPI0407176B8 (pt) | 2021-05-25 |
| JP2006516405A (ja) | 2006-07-06 |
| ATE496115T1 (de) | 2011-02-15 |
| CN1777670A (zh) | 2006-05-24 |
| SE0300245D0 (sv) | 2003-01-31 |
| DE602004031079D1 (de) | 2011-03-03 |
| EP1587913B1 (en) | 2011-01-19 |
| BRPI0407176B1 (pt) | 2018-05-08 |
| SE0300245L (sv) | 2004-08-01 |
| BRPI0407176A (pt) | 2006-02-07 |
| PL212096B1 (pl) | 2012-08-31 |
| US7947482B2 (en) | 2011-05-24 |
| WO2004067731A1 (en) | 2004-08-12 |
| ES2362496T3 (es) | 2011-07-06 |
| RU2352628C2 (ru) | 2009-04-20 |
| RU2005127331A (ru) | 2006-01-27 |
| US20060269533A1 (en) | 2006-11-30 |
| AU2004208084B2 (en) | 2008-10-09 |
| CA2514659A1 (en) | 2004-08-12 |
| AU2004208084A1 (en) | 2004-08-12 |
| DK1587913T3 (da) | 2011-04-11 |
| CN100558883C (zh) | 2009-11-11 |
| SE526711C2 (sv) | 2005-10-25 |
| CA2514659C (en) | 2014-07-08 |
| EP1587913A1 (en) | 2005-10-26 |
| JP4540664B2 (ja) | 2010-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI90086C (fi) | Foerfarande foer isolering av en terapeutiskt anvaendbar lactobacillus acidophilus -stam | |
| CA2787544C (en) | Probiotic composition for use in the treatment of bowel inflammation | |
| PL378435A1 (pl) | Nowe szczepy Bifidobacterium zdolne do wytwarzania glutaminy | |
| JP2019520340A5 (pl) | ||
| CN114206362A (zh) | 炎性状况和相关感染的治疗方法 | |
| ITFI990051A1 (it) | Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio | |
| CN108157703A (zh) | 一种蔓越莓菊粉益生菌固体饮料及其制备方法 | |
| CN108836956B (zh) | 甘草查耳酮a在制备治疗鸡坏死性肠炎药物中的用途 | |
| CN113755409A (zh) | 一种缓解胰岛素抵抗的长双歧杆菌及其应用 | |
| CN117281839A (zh) | 萨利尔斯氏拟杆菌csp6在制备治疗和/或预防炎症性肠病的药物及食品中的应用 | |
| CN102813910B (zh) | 一种用于防治禽类气囊炎的药物组合物及其制备方法 | |
| CN108309969B (zh) | 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途 | |
| Zhou et al. | Administration of probiotics reduces bacterial translocation after intestinal transplantation in rats | |
| CN108853081B (zh) | 穗花杉双黄酮在制备治疗鸡坏死性肠炎的药物中的用途 | |
| KR20130116440A (ko) | 5-아자시티딘을 유효성분으로 함유하는 바이오필름에 의해 유발되는 감염증의 예방 또는 치료용 약학적 조성물 | |
| JP2023504887A (ja) | サルモネラ菌ｉｉｉ型分泌系阻害剤の製造におけるミリセチンの使用 | |
| JP7118594B2 (ja) | 止瀉剤組成物 | |
| Snel et al. | The influence of indigenous segmented filamentous bacteria on small intestinal transit in mice | |
| Marshall Jr et al. | The variable effects of sulfonamides on fecal bacteria in patients with chronic ulcerative colitis: a preliminary report | |
| GB1585863A (en) | Pharmaceutical lactobacillus preparations | |
| CN116478874B (zh) | 一种改善慢性低度炎症的副干酪乳杆菌及其应用 | |
| CN107073018A (zh) | 尿路感染的治疗 | |
| JP2007522075A (ja) | 肝不全の治癒並びに肝臓代謝の再生及び強化のためのエンテロコッカス・フェシウム（ＥｎｔｅｒｏｃｏｃｃｕｓＦａｅｃｉｕｍ）菌株の使用 | |
| EP4404939A1 (en) | Hygromycin a for treatment of diseases and infections | |
| PAQUIN | ANTI-TUBERCLE SERUM. THE TREATMENT OF CONSUMPTION BY SEROTHERAPY—REPORT AND PRESENTATION OF CASES TREATED—EXHIBITION OF SERUM, ETC. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RECP | Rectifications of patent specification |